Jul 11, 2024 · Most patients who took foralumab nasal spray for at least six months as part of an expanded use program for nonactive secondary progressive MS saw a reduction in microglia activity in the brain. Patients also reported less fatigue, a common symptom of MS. “Given that nasal foralumab dampens microglial inflammation in subjects with advanced progressive MS and microglial activation is a ...

Dec 9, 2024 · Axsome to ask FDA to approve AXS-05 for Alzheimer’s agitation. Axsome Therapeutics plans this year to ask the U.S. Food and Drug Administration (FDA) to approve its oral therapy AXS-05 as a treatment for agitation related to Alzheimer’s disease.

Recent Posts. Axsome to ask FDA to approve AXS-05 for Alzheimer’s agitation January 3, 2025; The holidays can be challenging for an Alzheimer’s caregiver December 9, 2024; Muna, GSK partner to develop targets for Alzheimer’s treatments December 6, 2024; Modified Kisunla dosing shown to lower risk of ARIA-E in Alzheimer’s November 8, 2024; The loss of …

Jul 18, 2022 · Consider the following before gently correcting your loved one: The present stage of dementia and your loved one’s ability to process information.; Is the behavior connected to dementia, or was it present before diagnosis and indicative of the person’s core personality?

Jun 27, 2024 · That’s according to new data from a Phase 2/3 clinical trial (NCT05686044) that tested three doses of buntanetap against a placebo in more than 300 patients with the neurodegenerative disease. The new results were announced last week by buntanetap’s developer Annovis Bio.. APOE4 is a genetic variant that has been identified as one of the strongest risk factors for Alzheimer’s.

Aug 17, 2020 · With more than 5 million people in the United States living with Alzheimer’s disease, most of us either know someone who has been diagnosed or are acquainted with a caregiver.Our initial response might be pity, but caregivers and patients with Alzheimer’s disease don’t want pity, though we do long to have someone understand what we’re going through.

Jan 25, 2021 · The device uses gamma frequency technology — called GENUS, for gamma entrainment using sensory stimuli — as a way to stimulate the brain in a non-invasive way.This can be done as an auditory (via sound) or visual (via light) stimulation. In mouse models of Alzheimer’s disease, researchers had already observed that, prior to the onset of cognitive decline, the brain showed a pattern of ...

Feb 8, 2024 · Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease.. Top-line results from the RETHINK-ALZ trial (NCT04994483) are expected by the end of this year, according to simufilam’s developer Cassava Sciences.Results from the second study, REFOCUS-ALZ study (NCT05026177), are ...

Jul 29, 2024 · My mother was a faithful, caring, loving daughter and caregiver to her parents, who lived into their 90s. She doted on them and was available day or night, though they were blessed to stay in their own home with the assistance of a grandchild who lived with them during the week.

Nov 8, 2024 · The modified dosing regimen reduced ARIA-E the most in patients with two copies of the ApoE4 gene variant, which is known to have a high genetic risk for Alzheimer’s. With the modification, 19% of these patients experienced ARIA-E compared with 57% on the standard dosing regimen, lowering their relative risk by 67%, according to Eli Lilly.